Top

Published in:

Open Access 01-11-2012 | Meeting abstract

Value and specificity of rare diseases business model-is the pursuit of this societal priority sustainable?

Authors: M Dunoyer, P Rollet

Published in: Orphanet Journal of Rare Diseases | Special Issue 2/2012

Excerpt

With less than 90 diseases covered by approved treatments in Europe for approximately 7,000 rare diseases described, patients with rare diseases are underserved. …

Mc Cabe. 2010

Schey C: 2011

CEPS report 2009, 2009 OD sales compared to total pharmaceutical sales. IMS data.

AFM report: 2011

Cote T: 2012

Title: Value and specificity of rare diseases business model-is the pursuit of this societal priority sustainable?
Authors: M Dunoyer
P Rollet
Publication date: 01-11-2012
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue Special Issue 2/2012
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/1750-1172-7-S2-A23

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Value and specificity of rare diseases business model-is the pursuit of this societal priority sustainable?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2012

National plans: case study Belgium

Rare family days: a family empowerment programme

Leveraging existing opportunities for improved Orphan Drug approval in the EU

Listening to children’s and parents’ voices: using patient reported outcomes to empower patients with orphan diseases and their parents

Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)

Exon skipping for DMD